Sinovation (Beijing) Medical Technology Co., Ltd. is a national high-tech enterprise focusing on the R&D, production, and sales of precise surgical medical devices for neurosurgery. It is committed to providing comprehensive and precise solutions for the diagnosis and treatment of neurosurgical diseases. Focusing on complex brain diseases such as epilepsy, brain tumors, and cerebral hemorrhage, and centering on core clinical needs such as surgical precision, safety, and efficiency, the company has built a full-process integrated product matrix covering pre-operative diagnostic and planning, intra-operative navigation/localization/treatment, and post-operative monitoring/evaluation. It is one of the very few domestic manufacturers in China that has established a full-process product layout in the field of precise neurosurgery, successfully filling the gaps in various types of high-end medical devices in this field.
The company has established a product matrix represented by the intracranial electrode series, neurosurgical robotics series, neuronavigation series, and the magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) system. A total of 12 products of the company have obtained NMPA Class III medical device registration certificates, 7 products have entered the national special review and approval procedure for innovative medical devices, and 5 products have been approved as national innovative medical devices, demonstrating outstanding R&D innovation conversion efficiency and hard-core technical strength. The company continues to cultivate technological innovation, with its products repeatedly winning national innovation certifications and ranking among the top tier of medical device innovation in China.
The company has taken the lead in undertaking more than ten national and provincial-level major scientific research projects, such as the Ministry of Science and Technology's "14th Five-Year Plan" National Key R&D Program, and the 2024 High-end Medical Equipment Promotion and Application Project by the Ministry of Industry and Information Technology (MIIT) and the National Health Commission (NHC). It has been awarded the title of National Key "Little Giant" Enterprise, and recognized as a winning unit in the Artificial Intelligence Medical Device Innovation Task by the MIIT, receiving authoritative recognition for its technological innovation capabilities and industry-leading position.
The company not only focuses on technological innovation but also emphasizes providing high-quality solutions for the healthcare industry to enhance medical diagnosis and treatment levels, thereby driving continuous progress in medical technology. Sinovation, joining hands with the medical industry to co-create the future of intelligent healthcare.
| April | Sinovation signed a contract to participate in the establishment of the Daxing Joint Fund of the Beijing Natural Science Foundation. The MRI-monitored semiconductor laser therapy equipment was selected for the "List of 100 New Technologies and Products" at the 2024 Zhongguancun Forum. |
| August | Sinovation was approved by the MIIT and the National Medical Products Administration (NMPA) as a "Winning Unit in the Artificial Intelligence Medical Device Innovation Task". |
| September | China's first brain and spine surgery robot, X1000, was approved for the market. The MRI-monitored semiconductor laser therapy equipment was selected for the "Beijing 2024 Catalog of the First Set (Piece) of Major Technical Equipment". |
| November | China's first neurosurgical planning software with independent intellectual property rights was approved for marketing by the NMPA. |
| April | China's first minimally invasive intracranial laser therapy product, LITT, was approved for the market. |
| May | Completed Series D+ financing. |
| June | Won the Second Prize of the Technology Invention Award of the Ministry of Education. |
| June | The world's first 3D structured light surgery robot was approved by the FDA for marketing. |
| August | China's first intracranial thermocoagulation depth electrode was approved for the market. |
| December | SR1-3D and Q300 series neurosurgical robots were selected for the "Beijing 2023 Catalog of the First Set (Piece) of Major Technical Equipment". The Q300 series miniature neurosurgical robot won the "2023 Top Ten Independent Innovative Medical Device Products Award". |
| January | China's first miniature neurosurgical robot, Q300 series, was approved for the market. |
| April | Neurosurgical planning software entered the NMPA innovative review channel. |
| August | Certified as a national-level "Little Giant" enterprise with Specialization, Refinement, Uniqueness, and Novelty. |
| October | Certified as a National Intellectual Property Demonstration Enterprise. |
| November | The R&D of the next-generation LITT was approved for the "14th Five-Year Plan" National Key R&D Program. |
| December | Completed Series D financing, and intracranial electrode manufacturer HKHS became a wholly-owned subsidiary. |
| January | Won the Second Prize of the Chinese Medical Science and Technology Award. |
| March | Recognized as a winning unit in the first phase of the Artificial Intelligence Industry Innovation Task by the MIIT. |
| July | SR series neurosurgical robots were selected for the "Excellent Domestic Equipment Product Catalog" of the National Health Commission. |
| October | Established China's first neurosurgical robot training center. |
| December | Won the First Prize of the Huaxia Medical Science and Technology Award. The cumulative number of surgeries exceeded 10,000 cases. |
| June | Completed strategic financing. |
| July | SR series neurosurgical robots were awarded the title of Zhongguancun's First Set (Piece) of Major Technical Equipment. |
| December | SR1-3D neurosurgical robot was approved for the market. Completed Series C financing. Q300 series miniature neurosurgical robot entered the NMPA innovative review channel. In 2020, neurosurgical robot products surpassed imported products to achieve market leadership. |
| September | Completed Series B financing. |
| December | NS1 series neuronavigation system was approved for the market by the NMPA. China's first LITT system entered the NMPA innovative review channel. Undertook the MIIT's core technology task for "neurosurgical surgery robots". |
| February | Completed Series A financing. |
| August | Neurosurgical robot SR1 completed clinical trials. |
| September | Surgical navigation R&D was approved for the "13th Five-Year Plan" National Key R&D Program. |
| December | Neurosurgical robot SR1 was approved for the market by the NMPA. |
| March | Neurosurgical robot SR1 was approved to enter the NMPA innovative review channel. |
| May | Neurosurgical robot entered the product prototype development stage. |
| Sinovation (Beijing) Medical Technology Co., Ltd. was established. |
| Neurosurgical robot entered the experimental validation stage. |
| Launched the R&D of neurosurgical robots. |
| HKHS obtained China's first Class III medical device registration certificate for the intracranial depth electrode. |
| HKHS obtained China's first Class III medical device registration certificate for the intracranial cortical electrode. |
| Tsinghua University collaborated with clinical institutions to carry out the research and development of the first generation of neurosurgical navigation system in China |
| HKHS was established. |
| Began production of China's first intracranial electrode product. |
| The team began developing China's first intracranial electrode product. |
